🇺🇸 FDA
Pipeline program

SHR-A2009 ; Aumolertinib

SHR-A2009-302

Phase 3 small_molecule active

Quick answer

SHR-A2009 ; Aumolertinib for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Suzhou Ribo Life Science Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Suzhou Ribo Life Science Co.
Indication
Non-small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials